Contact your healthcare provider immediately if you experience severe symptoms like chest pain, difficulty breathing, or blood sugar levels below 54 mg/dL
Nasal spray risks include mucosal irritation, unknown systemic absorption levels leading to either underdosing or unpredictable dosing, and preservative-related side effects
Low), and in individuals with T2DM and established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk (Class IV
No significant toxicity indicators reported during the preclinical trials
Laboratory research demonstrates efficacy in bleomycin-induced pulmonary fibrosis mouse models, with treated groups showing milder pathologic changes and less collagen deposition compared to controls
No clinical, diagnostic, human, or veterinary use